• Newsletters
  • Facebook
  • Twitter
Friday, September 22, 2017
View complete forecast
News-Sentinel.com Your Town. Your Voice.

Indiana board revokes license of New England compounding pharmacy tied to fatal meningitis

Copyright 2014 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.The Associated Press
Tuesday, February 12, 2013 12:42 pm
The Indiana Board of Pharmacy agreed to revoke the New England Compounding Center’s license for its connection to the fatal meningitis outbreak.The Massachusetts-based pharmacy reached a voluntary revocation agreement Friday with Indiana Attorney General Greg Zoeller’s office, which the board approved Monday in Indianapolis, according to a news release from Zoeller's office.

“Public health and safety is a top priority and today’s action was a necessary step to ensure this company, which put patients unnecessarily at risk, does not operate within our state’s borders going forward,” Zoeller said in the release.

Zoeller said a license revocation means the company cannot operate in Indiana for at least seven years. The company could apply for a new license after that time, but the board would have to approve the license application.

In November, the Indiana Board of Pharmacy voted to indefinitely suspend the compounding pharmacy's non-resident pharmacy license and the Attorney General’s office recently filed a licensing complaint against the company. Zoeller said the pharmacy failed to ensure its epidural steroid injections were safe for patients, which led to devastating harm.

As of Feb. 4, the U.S. Centers for Disease Control and Prevention identified 10 deaths and 79 total cases of fungal meningitis in Indiana stemming from epidural steroid injections produced by the pharmacy. Nationwide, the outbreak involved 696 cases and 45 deaths across 20 states.


News-Sentinel.com reserves the right to remove any content appearing on its website. Our policy will be to remove postings that constitute profanity, obscenity, libel, spam, invasion of privacy, impersonation of another, or attacks on racial, ethnic or other groups. For more information, see our user rules page.
comments powered by Disqus